@article{9d34158f875b4e2087efa5a87d4af581,
title = "Reply to comments on “Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei”",
author = "Sakura Hiraide and Keigo Komine and Masanobu Takahashi and Chikashi Ishioka",
note = "Funding Information: Chikashi Ishioka received research funding from the Tokyo Cooperative Oncology Group. Chikashi Ishioka received contributions from Chugai Pharmaceutical, Asahi Kasei Pharma Corporation, Ono pharmaceutical, MSD, Pfizer, AstraZeneca, Bristol-Myers Squibb, Janssen Pharmaceutical, Taiho Pharmaceutical, Eisai Pharmaceutical, Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical. Masanobu Takahashi has received research funding from Ono Pharmaceutical Company. Chikashi Ishioka is a representative of Tohoku Clinical Oncology Research and Education Society, a specified non-profit corporation. ",
year = "2021",
month = mar,
doi = "10.1007/s10147-021-01878-z",
language = "English",
volume = "26",
pages = "621",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "3",
}